气道炎症与吸烟状态同哮喘或慢阻肺患者痰液IL-33水平的关联
该研究探讨哮喘或慢阻肺患者中吸烟状态与气道炎症表型同痰液IL-33水平的关联。基于摘要信息,研究提示在慢阻肺既往吸烟者中靶向IL-33可能有益且需考虑疾病严重程度,在重症哮喘中靶向IL-33可能是潜在治疗选择且与T2状态无关。
要点
- 慢阻肺既往吸烟者靶向IL-33可能有益,但需考虑疾病严重程度。
- 重症哮喘靶向IL-33可能是潜在治疗选择,与T2状态无关。
- 需进一步明确哪些患者可能从抗IL-33治疗中获益。
核心结论
- 在慢阻肺患者中,靶向IL-33对既往吸烟者可能有益,但疾病严重程度也应考虑。
- 在重症哮喘患者中,靶向IL-33可能是潜在治疗选择,与T2状态无关。
主要发现
- 临床前/临床研究显示靶向IL-33及其ST2受体的单克隆抗体在哮喘和慢阻肺中具有 promising 疗效。
- 既往研究报道吸烟状态可能影响IL-33蛋白水平。
临床怎么用
- 对慢阻肺既往吸烟者考虑抗IL-33治疗时需结合疾病严重程度评估。
- 重症哮喘患者无论T2状态如何均可考虑抗IL-33治疗作为潜在选择。
局限性
- 目前对哮喘或慢阻肺患者中IL-33水平升高相关气道炎症特征知之甚少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with COPD, targeting IL-33 might be auspicious in former smokers. However, disease severity should also be considered. In patients with severe asthma, targeting IL-33 might be a potential treatment option, irrespective of T2-status. https://bit.ly/3SFspww Asthma and COPD are heterogeneous inflammatory airway conditions. Interleukin (IL)-33 is an epithelial pleiotropic cytokine that regulates type 1 and type 2 immune responses [1]. Clinical trials have shown promising efficacy of monoclonal antibodies targeting IL-33 and its ST2 receptor in asthma and COPD [2–4]. So far, little is known about the characterisation of airway inflammation associated with increased IL-33 levels in patients with asthma or COPD. Moreover, previous studies have reported a potential impact of smoking status on IL-33 protein levels [5]. Therefore, we investigated the association of smoking status and airway inflammatory phenotypes with IL-33 levels in patients with asthma or COPD. Such clinical characterisation could provide new insights for selecting patients who might benefit from anti-IL-33 therapy.
引用
- Abdo M, Pedersen F, Kirsten AM, et al. Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD. Eur Respir J. 2024. PMID: 39147409. doi:10.1183/13993003.00347-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。